

- Para MF, Meehan P, Holden-Wiltse J et al. (1999). ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. *Antimicrob Agents Chemother* **43**: 1373.
- Peterson PK, Gekker G, Hu S, Chao CC (1994). Anti-human immunodeficiency virus type 1 activities of U-90152 in human brain cell cultures. *Antimicrob Agents Chemother* **38**: 2465.
- PubChem Open Chemistry Database. [pubchem.ncbi.nlm.nih.gov/compound/Delavirdine#section=Top](http://pubchem.ncbi.nlm.nih.gov/compound/Delavirdine#section=Top). Accessed 17 March 2017.
- Roberts AD, Liappis AP, Chinn C et al. (2002). Effect of delavirdine on plasma lipids and lipoproteins in patients receiving antiretroviral therapy. *AIDS* **16**: 1829.
- Romero DL, Busso M, Tan CK et al. (1991). Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. *Proc Natl Acad Sci U S A* **88**: 8806.
- Romero DL, Morge RA, Biles C et al. (1994). Discovery, synthesis and bioactivity of bis(heteroaryl)piperazines. 1. A novel class of non-nucleoside HIV-1 reverse transcriptase inhibitors. *J Med Chem* **37**: 999.
- Shelton MJ, Hewitt RG, Adams JM et al. (2003a). Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity. *J Clin Pharmacol* **43**: 171.
- Shelton MJ, Hewitt RG, Adams J et al. (2003b). Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. *Antimicrob Agents Chemother* **47**: 1694.
- Smith PF, Dicenzo R, Forrest A et al. (2005). Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. *Clin Pharmacokinet* **44**: 99.
- Uhlmann EJ, Tebas P, Storch GA et al. (2004). Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine. *J Clin Virol* **31**: 198.
- Voorman RL, Maio SM, Hauer MJ et al. (1998b). Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A. *Drug Metab Dispos* **26**: 631.
- Voorman RL, Maio SM, Payne NA et al. (1998a). Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. *J Pharmacol Exp Ther* **287**: 381.
- Voorman RL, Payne NA, Wienkers LC et al. (2001). Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6. *Drug Metab Dispos* **29**: 41.